MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 329004 | Name: Eberconazole Nitrate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Eberconazole Nitrate, also known as Ebernet, is an azole antifungal agent and broad-spectrum imidazole derivative. Eberconazole Nitrate is effective in dermatophytoses, candidiasis, and pityriasis treatment.

Chemical Structure

Eberconazole Nitrate
Eberconazole Nitrate
CAS#130104-32-4 (nitrate)

Theoretical Analysis

MedKoo Cat#: 329004

Name: Eberconazole Nitrate

CAS#: 130104-32-4 (nitrate)

Chemical Formula: C18H15Cl2N3O3

Exact Mass: 0.0000

Molecular Weight: 392.24

Elemental Analysis: C, 55.12; H, 3.85; Cl, 18.08; N, 10.71; O, 12.24

Price and Availability

Size Price Availability Quantity
100mg USD 950.00 2 Weeks
1g USD 3,450.00 2 Weeks
2g USD 6,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
130104-32-4 (nitrate) 128326-82-9 (free base)
Synonym
Eberconazole Nitrate; Ebernet; Eberconazol; Eberconazolum; Eberconazole mononitrate; Eberconazole, nitric acid;
IUPAC/Chemical Name
1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-1H-imidazole nitrate
InChi Key
DPHMSVRBAXJSPF-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H14Cl2N2.HNO3/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22;2-1(3)4/h1-4,7-11,18H,5-6H2;(H,2,3,4)
SMILES Code
ClC1=C(C(N2C=CN=C2)C3=CC=CC=C3CC4)C4=CC(Cl)=C1.[O-][N+](O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related CAS# 128326-82-9(Eberconazole ) 130104-32-4(Eberconazole Nitrate)

Preparing Stock Solutions

The following data is based on the product molecular weight 392.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Moodahadu-Bangera LS, Martis J, Mittal R, Krishnankutty B, Kumar N, Bellary S, Varughese S, Rao PK. Eberconazole--pharmacological and clinical review. Indian J Dermatol Venereol Leprol. 2012 Mar-Apr;78(2):217-22. doi: 10.4103/0378-6323.93651. PMID: 22421664. 2: Eberconazole. WAS 2160. Drugs R D. 1999 Feb;1(2):168-9. doi: 10.2165/00126839-199901020-00012. PMID: 10566015. 3: Ravichandran M, Srikanth S, Kumar BA, Munusamy R. Efficacy and Safety of Eberconazole vs Sertaconazole in Localised Tinea Infection. Indian J Dermatol. 2021 Sep-Oct;66(5):573. doi: 10.4103/ijd.IJD_893_20. PMID: 35068526; PMCID: PMC8751703. 4: Eberconazole (Eberconazol, Eberconazole nitrate, WAS 2160). Drugs R D. 2002;3(5):352-4. doi: 10.2165/00126839-200203050-00011. PMID: 12455157. 5: Barbanoj MJ, Antonijoan R, García-Gea C, Puntes M, Gich I, Jané F. Eberconazole cream: topical and general tolerability, sensitisation potential, and systemic availability. Methods Find Exp Clin Pharmacol. 2005 May;27(4):227-34. doi: 10.1358/mf.2005.27.4.893581. PMID: 16082423. 6: Lee A, Tysome JR, Saeed SR. Topical azole treatments for otomycosis. Cochrane Database Syst Rev. 2021 May 25;5(5):CD009289. doi: 10.1002/14651858.CD009289.pub2. PMID: 34033120; PMCID: PMC8147581. 7: Repiso Montero T, López S, Rodríguez C, del Rio R, Badell A, Gratacós MR. Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomized, double-blind, comparative trial with miconazole 2% cream. Int J Dermatol. 2006 May;45(5):600-4. doi: 10.1111/j.1365-4632.2006.02841.x. PMID: 16700802. 8: de la Paz Cota BR, Cepero Vega PP, Matus Navarrete JJ, Aguado Mulgado GE, Narváez Huerta JJ, Lamadrid Bautista E, Fiscal Chauteco E. Efficacy and safety of eberconazole 1% otic solution compared to clotrimazole 1% solution in patients with otomycosis. Am J Otolaryngol. 2018 May-Jun;39(3):307-312. doi: 10.1016/j.amjoto.2018.03.017. Epub 2018 Mar 6. PMID: 29551350. 9: Sharma J, Kaushal J, Aggarwal K. A Comparative Study of Efficacy and Safety of Eberconazole versus Terbinafine in Patients of Tinea Versicolor. Indian J Dermatol. 2018 Jan-Feb;63(1):53-56. doi: 10.4103/ijd.IJD_126_17. PMID: 29527026; PMCID: PMC5838755. 10: Rubin AI, Bagheri B, Scher RK. Six novel antimycotics. Am J Clin Dermatol. 2002;3(2):71-81. doi: 10.2165/00128071-200203020-00001. PMID: 11893219. 11: del Palacio A, Ortiz FJ, Pérez A, Pazos C, Garau M, Font E. A double-blind randomized comparative trial: eberconazole 1% cream versus clotrimazole 1% cream twice daily in Candida and dermatophyte skin infections. Mycoses. 2001;44(5):173-80. doi: 10.1046/j.1439-0507.2001.00632.x. PMID: 11486455. 12: Torres-Rodríguez JM, Madrenys-Brunet N, Montsant L. Tratamiento tópico de la candidosis cutánea experimental del cobayo con eberconazol [Topical treatment with eberconazole of the experimental guinea pig cutaneous candidosis.]. Rev Iberoam Micol. 1999 Mar;16(1):43-5. Spanish. PMID: 18473592. 13: Choudhary SV, Aghi T, Bisati S. Efficacy and safety of terbinafine hydrochloride 1% cream vs eberconazole nitrate 1% cream in localised tinea corporis and tinea cruris. Indian Dermatol Online J. 2014 Apr;5(2):128-31. doi: 10.4103/2229-5178.131079. PMID: 24860743; PMCID: PMC4030336. 14: Tomás JM, Camprubí S, Merino S, Parés R, Llauradó X, Julve J. Inhibition of two imidazole antimycotics, eberconazole and clotrimazole, by different components of Candida albicans serotype B membrane protoplasts. Int J Antimicrob Agents. 1993 Jul;3(1):61-4. doi: 10.1016/0924-8579(93)90006-q. PMID: 18611545. 15: Sharma N, Rao SS, Vaghela B. Validated Stability-indicating High-performance Liquid Chromatographic Method for Estimation of Degradation Behaviour of Eberconazole Nitrate and Mometasone Furoate in Cream Formulation. Indian J Pharm Sci. 2013 Jan;75(1):76-82. doi: 10.4103/0250-474X.113530. PMID: 23901164; PMCID: PMC3719153. 16: Gnaneshwar R, Kumar AS, Carol F, Martis J, Jerajani HR, Kuruvila M, Latha MS, Krishnankutty B. The Efficacy and Safety of Eberconazole Nitrate 1% and Mometasone Furoate 0.1% w/w Cream in Subjects with Inflamed Cutaneous Mycoses. Rev Recent Clin Trials. 2015;10(2):161-70. doi: 10.2174/157488711002150714141234. PMID: 26216438. 17: Fernández-Torres B, Inza I, Guarro J. Evaluation of disk diffusion method for determining eberconazole susceptibility of dermatophytes and influence of culture medium. Antimicrob Agents Chemother. 2005 May;49(5):2116-8. doi: 10.1128/AAC.49.5.2116-2118.2005. PMID: 15855542; PMCID: PMC1087668. 18: Bothiraja C, Gholap AD, Shaikh KS, Pawar AP. Investigation of ethyl cellulose microsponge gel for topical delivery of eberconazole nitrate for fungal therapy. Ther Deliv. 2014 Jul;5(7):781-94. doi: 10.4155/tde.14.43. PMID: 25287385. 19: del Palacio A, Cuétara S, Rodríguez Noriega A. Topical treatment of tinea corporis and tinea cruris with eberconazole (WAS 2160) cream 1% and 2%: a phase II dose-finding pilot study. Mycoses. 1995 Jul-Aug;38(7-8):317-24. doi: 10.1111/j.1439-0507.1995.tb00415.x. PMID: 8559197. 20: Torres-Rodríguez JM, Mendez R, López-Jodra O, Morera Y, Espasa M, Jimenez T, Lagunas C. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Antimicrob Agents Chemother. 1999 May;43(5):1258-9. doi: 10.1128/AAC.43.5.1258. PMID: 10223946; PMCID: PMC89253.

View History

D4-Ribavirin

D4-Ribavirin